Answers are grounded in this paper and cite their sources.
The growth of both target discovery and innovative drug design has sparked a lot of excitement for the future of how we treat Parkinson's disease. Given the immense focus on LRRK2 as a therapeutic target, it is expected within the next decade to determine its therapeutic properties, or lack thereof, for PD.
No takes yet. Share an insight, caveat, or question.
Kluss et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: